Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Income from Continuing Operations (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Income from Continuing Operations for 5 consecutive years, with 101994000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 96.07% to 101994000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 35989000.0 through Dec 2025, down 2168.33% year-over-year, with the annual reading at 171298000.0 for FY2025, 60429.33% down from the prior year.
  • Income from Continuing Operations hit 101994000.0 in Q4 2025 for ARS Pharmaceuticals, up from 53192000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 101994000.0 in Q4 2025 to a low of 53192000.0 in Q3 2025.
  • Historically, Income from Continuing Operations has averaged 5031750.0 across 5 years, with a median of 16710500.0 in 2022.
  • Biggest YoY gain for Income from Continuing Operations was 397.08% in 2023; the steepest drop was 224.76% in 2023.
  • Year by year, Income from Continuing Operations stood at 46623000.0 in 2021, then plummeted by 133.12% to 15443000.0 in 2022, then soared by 397.08% to 45878000.0 in 2023, then increased by 13.39% to 52020000.0 in 2024, then skyrocketed by 96.07% to 101994000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SPRY at 101994000.0 in Q4 2025, 53192000.0 in Q3 2025, and 47614000.0 in Q2 2025.